touchPODCAST

Primary biliary cholangitis: Appraising the changing therapeutic landscape

touchEXPERT OPINIONS for touchIMMUNOLOGY

Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis. 

The expert

Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchimmunologyime.org/Primary-biliary-cholangitis-therapeutic-landscape

Primary biliary cholangitis: Appraising the changing therapeutic landscape

touchEXPERT OPINIONS for touchENDOCRINOLOGY

Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis. 

The expert

Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchendocrinologyime.org/primary-biliary-cholangitis-therapeutic-landscape

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4

touchMDT for touchONCOLOGY

Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

www.touchONCOLOGY.com 

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3

touchMDT for touchONCOLOGY

Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

www.touchONCOLOGY.com 

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4

touchMDT for touchRESPIRATORY

Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

www.touchRESPIRATORY.com

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3

touchMDT for touchRESPIRATORY

Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

www.touchRESPIRATORY.com

touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?

touchMDT for touchRESPIRATORY

What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?

Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects.

The multidisciplinary team

Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands

Pulmonologist – Dr Lizza Hendriks, 
Maastricht University Medical Center, Maastricht, The Netherlands

Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 
https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?

touchMDT for touchRESPIRATORY

What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights.

The multidisciplinary team

Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA

Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 
https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

touchMDT for touchRESPIRATORY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?

touchMDT for touchRESPIRATORY

What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.

The multidisciplinary team:

Pulmonologist – Dr Lizza Hendriks, 
Maastricht University Medical Center, Maastricht, The Netherlands

Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 
https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

touchMDT for touchONCOLOGY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?

touchMDT for touchONCOLOGY

What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?

Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects.

The multidisciplinary team

Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands

Pulmonologist – Dr Lizza Hendriks, 
Maastricht University Medical Center, Maastricht, The Netherlands

Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/